CJC-1295 with DAC is a synthetic analog of growth hormone–releasing hormone (GHRH) that includes a drug affinity complex (DAC) modification intended to prolong its duration of action. It is frequently referenced in experimental and wellness circles as a long-acting GH-axis peptide.

Regulatory status and product standards for CJC-1295 with DAC vary, and many marketed uses are not part of mainstream, guideline-based endocrine practice.

Like GHRH, CJC-1295 with DAC acts at the pituitary to stimulate growth hormone secretion, which in turn influences IGF-1 and downstream metabolic pathways. The DAC modification is intended to extend the peptide’s half-life and sustain GH/IGF-1 stimulation over a longer window.

The physiologic effects depend on baseline GH-axis integrity, dose, and co-administered agents, as well as on how protocols are structured in practice.

CJC-1295 with DAC is largely discussed in experimental and wellness contexts rather than as a widely approved therapy for GH deficiency. It may appear in discussions around body composition, perceived vitality, or sleep, but such uses often sit outside formal labeling.

For individuals with suspected GH-axis disorders, clinicians typically rely on established diagnostic criteria and better-characterized therapies. Any consideration of CJC-1295 with DAC should be evaluated against local regulations and expert guidance.

CJC-1295 is classified as a prohibited substance by WADA under category S2.

Notable athlete sanctions involving CJC-1295 include:

• Joey Coste (CrossFit): Received a 4-year sanction in 2022 for use of CJC-1295 and Ipamorelin.
• Ondrej Slezak (Cycling): Received a 4-year ban for multiple violations including CJC-1295 use.

Described effects include injection-site reactions, flushing, headache, and changes in sleep or energy patterns. Because the peptide modulates the GH/IGF-1 axis, there are theoretical concerns about impacts on glucose metabolism, fluid balance, and tissue growth, especially with longer-term use.

These considerations highlight the importance of clinician oversight and a cautious approach to interpreting claims about benefits.

CJC-1295 with DAC has a half-life of 6–8 days due to its affinity for serum albumin, supporting infrequent dosing.

This information summarizes commonly discussed research practices and does not constitute medical advice.

CJC-1295 with DAC commonly appears in catalogs as a lyophilized powder for reconstitution. It is often discussed in combination concepts, such as pairing with GH secretagogues, to target multiple points in the GH axis.

Structural listings in this catalog simply enumerate vial codes and specifications. They do not endorse specific combination strategies or contexts of use.

Research on CJC-1295 and related GHRH analogs has examined GH/IGF-1 responses, tolerability, and potential effects on body composition or metabolic markers. The evidence base is smaller and more heterogeneous than for established GH therapies.

Claims about long-term benefits should therefore be interpreted cautiously and weighed against uncertainties around safety and comparative effectiveness.

Future FAQs may explore how CJC-1295 with DAC differs conceptually from shorter-acting GHRH analogs, how clinicians think about long-acting GH-axis modulation, and how benefit–risk is assessed. Answers will remain educational and non-prescriptive.